Burden and disparities of hematologic malignancies in the Andean countries: a GLOBOCAN 2022 analysis of incidence, mortality, and mortality-to-incidence ratios

Imagine the human body as a bustling, high-tech city. Usually, the construction crews (cells) follow strict blueprints, building new neighborhoods and repairing old ones with perfect precision. But sometimes, the blueprints get corrupted, and the crews go rogue, building chaotic, useless structures that crowd out the good ones. This is cancer. While we often hear about the big, visible construction disasters like lung or skin cancer, there's a quieter, sneakier group of troublemakers: blood cancers. These are the "hematologic malignancies." They don't always form a single lump you can see; instead, they mess with the city's delivery trucks (white blood cells), its waste management (red blood cells), or its security guards (lymphocytes).

Why do we care about tracking these invisible invaders? Because not every city handles them the same way. Some cities have super-advanced radar systems that spot the trouble early, while others might miss the signs until the chaos is already widespread. Scientists use a tool called GLOBOCAN, which acts like a global weather map for cancer, collecting data on how many new cases appear (incidence) and how many people pass away from them (mortality). By comparing these numbers across different countries, researchers can figure out if a high number of cases means the disease is actually more common, or if it just means the city has better eyes to see it. This is crucial because if we don't know where the real trouble lies, we can't send the right help.

---

The Andean Mystery: A Tale of Four Cities and Their Blood Cancers

In this study, a team of researchers decided to zoom in on a specific mountainous region in South America known as the Andean countries: Ecuador, Colombia, Venezuela, and Peru. Think of these four nations as four neighboring cities in the same mountain range, all facing similar challenges but running on different budgets and with different levels of technology. The researchers wanted to see how the "blood cancer" trouble was spreading in 2022, using data from the GLOBOCAN map.

They looked at four main types of blood cancer troublemakers:

1. Non-Hodgkin Lymphoma (NHL): The most common type of trouble, like a widespread, chaotic riot.
2. Leukemias: The deadliest type, acting like a fast-moving flood that drowns the city's defenses.
3. Hodgkin Lymphoma (HL): A rarer, more specific type of riot.
4. Multiple Myeloma (MM): A troublemaker that targets the city's bone factories.

What They Found: The Numbers Don't Lie, But They Can Be Tricky

When the researchers tallied up the numbers for 2022, they found a total of 18,826 new cases of blood cancer across these four countries, resulting in 13,253 deaths. That's a heavy toll.

Here is where the story gets interesting, like a detective noticing a clue that doesn't quite fit the usual pattern:

• The "High-Tech" City: Peru stood out with the highest number of new cases. For every 100,000 people, there were 28.7 new cases. Peru also had the highest death rate, with 16.1 deaths per 100,000 people.
• The "Lowest" City: Venezuela had the lowest death rate, with only 10.9 deaths per 100,000 people.
• The Middle Ground: Ecuador and Venezuela were tied for the second-highest number of new cases (22.2 per 100,000), while Colombia had the lowest number of new cases (21 per 100,000).

The Gender Gap
Just like in many other parts of the world, the researchers noticed that men were getting hit harder than women. In every single country and for every type of blood cancer, the "Male-to-Female" ratio was above 1.0. This means men were more likely to get these diseases and more likely to die from them. For example, in Peru, men were 1.71 times more likely to get Multiple Myeloma than women.

The "Survival Score" (MIR)
The researchers calculated something called the "Mortality-to-Incidence Ratio" (MIR). Think of this as a "Survival Score." If you have a high score, it means that for every person who gets the disease, a large number of them die. If the score is low, it suggests that more people are surviving.

• The Worst Score: Multiple Myeloma had the highest "death burden" with a ratio of 0.78. This means if 100 people get it, about 78 might die.
• The Best Score: Hodgkin Lymphoma had the lowest ratio at 0.32, suggesting better survival chances.
• Country Differences: Ecuador had the highest overall "death burden" relative to new cases (0.63), while Venezuela had the lowest (0.49).

The Big Twist: The "Richer is Better" Myth?
Usually, scientists expect that as a country gets richer and more developed (measured by something called the Human Development Index, or HDI), the death rate from cancer goes down. This is because richer countries usually have better hospitals and can catch diseases earlier.

But in this mountain region, the map looked different. Peru had the highest HDI (0.76) and also the highest death rate. Venezuela had the lowest HDI (0.69) but the lowest death rate. The researchers found a positive link: as the HDI went up, the death rate seemed to go up too.

So, What Does This Mean?
The authors suggest that this strange pattern isn't necessarily because being richer makes you sicker. Instead, they think it might be about how well the cities are counting.

• Better Eyes: Peru might have better hospitals and more doctors looking for cancer. This means they find more cases (high incidence) and record more deaths accurately.
• Missing Data: In countries with fewer resources, like Venezuela, they might be missing a lot of cases. If you don't find the sick people, you don't count them in the "new cases" list, and you might not even know they died from cancer. This could make the numbers look artificially low.

The study also noted that while older populations usually have more cancer, the country with the oldest people (Colombia, with a median age of 31.2) didn't have the highest cancer rates. This suggests that simply getting older isn't the only reason for the differences; the quality of the healthcare system and how well they keep records matters just as much.

The Bottom Line
This paper doesn't claim to have solved the mystery of why blood cancer hits these countries differently. Instead, it suggests that the numbers we see are a mix of real disease and how good a country is at finding and reporting it. The authors conclude that to fix the disparities, these countries need to strengthen their "surveillance systems"—basically, they need better ways to track who is getting sick and who is dying, so they can send help where it's truly needed, rather than just guessing based on incomplete maps.